Financial PerformanceFilspari's Q1 revenue was in line with consensus at $56MM, showing 13% quarter-over-quarter growth, maintaining momentum from an impressive Q4.
Market OpportunityThe large upside with FSGS approval is seen as a significant opportunity for TVTX, with competitors being at least 2-3 years behind.
Regulatory ProgressThe FDA accepted the supplemental New Drug Application for Filspari for the treatment of focal segmental glomerulosclerosis.